Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells

Francesca Chiarini, PhD, Cecilia Grimaldi, BS, Francesca Ricci, BS, Pierluigi Tazzari, MD, Ilaria Iacobucci, PhD, Giovanni Martinelli, MD, Pasqualepaolo Pagliaro, MD, James McCubrey, Sergio Amadori, MD, Alberto M Martelli, MD

Blood (2011) 118 (21): 2596.

https://doi.org/10.1182/blood.V118.21.2596.2596

Published: 2011

Journal Articles

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Matilde Y Follo, PhD, Cristina Clissa, MD, Sara Mongiorgi, PhD, Francesca Chiarini, PhD, Michele Baccarani, MD, Giovanni Martinelli, MD, PhD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2011) 118 (21): 4635.

https://doi.org/10.1182/blood.V118.21.4635.4635

Published: 2011

Journal Articles

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

Camilla Evangelisti, PhD, Francesca Chiarini, PhD, Francesca Ricci, BS, Pierluigi Tazzari, MD, Andrea Pession, MD, PhD, James A McCubrey, PhD, Alberto M. Martelli, MD

Blood (2010) 116 (21): 3242.

https://doi.org/10.1182/blood.V116.21.3242.3242

Published: 2010

Journal Articles

AMP-Dependent Kinase/mTOR Complex 1 Signaling In T-Cell Acute Lymphoblastic Leukemia: Therapeutical Implications

Cecilia Grimaldi, BS, Francesca Chiarini, PhD, Francesca Ricci, BS, Pierluigi Tazzari, MD, Michela Battistelli, PhD, Elisabetta Falcieri, MD, Andrea Pession, MD, PhD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2010) 116 (21): 3225.

https://doi.org/10.1182/blood.V116.21.3225.3225

Published: 2010

Journal Articles

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Sergio Amadori, MD, Adriano Venditti, MD, Emanuele Ammatuna, MD, Alberto M. Martelli, MD, Giovanna Meloni, MD, Fabrizio Pane, MD, Giovanni Martinelli, MD, Monia Lunghi, Livio Pagano, MD, Daniela Cilloni, MD, PhD, Vittorio Rizzoli, Francesco Di Raimondo, MD, Claudio Fozza, MD, Luciana Annino, MD, Alfonso Piciocchi, Edoardo La Sala, Paola Fazi, MD, Marco Vignetti, MD

Blood (2010) 116 (21): 510.

https://doi.org/10.1182/blood.V116.21.510.510

Published: 2010

Journal Articles

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Carla Filì, MD, Chiara Colombi, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Domenico Russo, MD, Lucia Manzoli, MD, Alberto M Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD

Blood (2010) 116 (21): 233.

https://doi.org/10.1182/blood.V116.21.233.233

Published: 2010

Journal Articles

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.

Francesca Chiarini, BS, Cecilia Grimaldi, BS, Francesca Ricci, BS, Pierluigi Tazzari, MD, Camilla Evangelisti, PhD, Andrea Pession, MD, PhD, Pasqualepaolo Pagliaro, MD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2009) 114 (22): 2025.

https://doi.org/10.1182/blood.V114.22.2025.2025

Published: 2009

Journal Articles

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Matilde Y Follo, PhD, Sara Mongiorgi, PhD, Cristina Clissa, MD, Francesca Chiarini, BS, Stefania Paolini, MD, Michele Baccarani, MD, Giovanni Martinelli, MD, Lucia Manzoli, MD, Alberto M. Martelli, MD, Carlo Finelli, MD, Lucio Cocco, MD, PhD

Blood (2009) 114 (22): 2384.

https://doi.org/10.1182/blood.V114.22.2384.2384

Published: 2009

Journal Articles

Erucylphosphohomocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.

Veronica Papa, BS, PierLuigi Tazzari, MD, Francesca Chiarini, BS, Francesca Ricci, BS, Giovanni Martinelli, MD, Andrea Bontadini, MD, James McCubrey, PhD, Lars H Lindner, MD, Hansjoerg Eibl, PhD, Alberto M. Martelli, MD

Blood (2008) 112 (11): 1330.

https://doi.org/10.1182/blood.V112.11.1330.1330

Published: 2008

Journal Articles

PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.

Francesca Chiarini, BS, Federica Fala, PhD, Francesca Ricci, BS, PierLuigi Tazzari, MD, Annalisa Astolfi, PhD, Andrea Pession, MD, PhD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2008) 112 (11): 1921.

https://doi.org/10.1182/blood.V112.11.1921.1921

Published: 2008

Journal Articles

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

PierLuigi Tazzari, MD, Veronica Papa, BS, Francesca Ricci, BS, Francesca Chiarini, BS, Camilla Evangelisti, PhD, Giovanni Martinelli, MD, Andrea Bontadini, MD, James McCubrey, PhD, Alberto M. Martelli, MD

Blood (2008) 112 (11): 957.

https://doi.org/10.1182/blood.V112.11.957.957

Published: 2008

Journal Articles

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

Carlo Finelli, MD, Matilde Y. Follo, PhD, Costanza Bosi, MD, Sara Mongiorgi, BS, Cristina Clissa, MD, Giovanni Martinelli, MD, Michele Baccarani, MD, Alberto M. Martelli, MD, PhD, Lucio Cocco, MD, PhD

Blood (2007) 110 (11): 2448.

https://doi.org/10.1182/blood.V110.11.2448.2448

Published: 2007

Journal Articles

The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.

James A. McCubrey, PhD, William L. Blalock, PhD, Pier Luigi Tazzari, MD, Alessandra Cappellini, PhD, Ilaria Iacobucci, PhD, Francesca Chiarini, BS, Steve L. Abrams, BS, Emanuela Ottaviani, PhD, Giovanni Martinelli, MD, Agostino Tafuri, MD, Lucio Cocco, MD PhD, Alberto M. Martelli, MD PhD, Federica Fala, MD

Blood (2007) 110 (11): 3344.

https://doi.org/10.1182/blood.V110.11.3344.3344

Published: 2007

Journal Articles

The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Alberto M. Martelli, MD, PhD, Veronica Papa, BS, Pier Luigi Tazzari, MD, Francesca Chiarini, BS, Alessandra Cappellini, PhD, Francesca Ricci, BS, Anna Maria Billi, PhD, Camilla Evangelisti, PhD, Steve L. Abrams, BS, Emanuela Ottaviani, PhD, Giovanni Martinelli, MD, James A. McCubrey, PhD

Blood (2007) 110 (11): 3355.

https://doi.org/10.1182/blood.V110.11.3355.3355

Published: 2007

Journal Articles

Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.

Steve L. Abrams, BS, Camilla Evangelisti, PhD, Francesca Chiarini, BS, Negin Misaghian, BS, Jorg Basecke, MD, Michele Millela, MD, Agostino Tafuri, MD, Massimo Libra, MD, Franca Stivala, MD, Marina Konopleva, MD, Michael Andreeff, MD, Linda S. Steelman, MS, Jacob Troppmair, PhD, Alberto M. Martelli, MD, James A. McCubrey, PhD

Blood (2007) 110 (11): 641.

https://doi.org/10.1182/blood.V110.11.641.641

Published: 2007

Journal Articles

Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.

James A. McCubrey, PhD, Steven L. Abrams, BS, Linda S. Steelman, MS, Ellis W.T. Wong, BS, William H. Chappell, MS, Jorg Basecke, MD, Franca Stivala, MD, Massimo Libra, MD, PhD, Michele Milella, MD, Agostino Tafuri, MD, Jacob Troppmair, PhD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Camilla Evangelisti, BS, Alberto M. Martelli, MD, PhD

Blood (2006) 108 (11): 1116.

https://doi.org/10.1182/blood.V108.11.1116.1116

Published: 2006

Journal Articles

Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients.

Costanza Bosi, MD, Carlo Finelli, MD, Alberto M. Martelli, MD, Maria Nyakern, Ph.D., Giovanni Martinelli, MD, Pier Luigi Tazzari, MD, Lucio Cocco, MD, Tiziana Grafone, PhD, Pier Paolo Piccaluga, MD, Baccarani Michele, MD

Blood (2005) 106 (11): 3432.

https://doi.org/10.1182/blood.V106.11.3432.3432

Published: 2005

NARROW

Temsirolimus, An Allosteric mTORC1 Inhibitor, Is Synergistic with Clofarabine in AML and AML Leukemia Initiating Cells

Effect of Lenalidomide Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients

Targeted Inhibition of mTORC1 and mTORC2 by the Active-Site mTOR Inhibitors, PP-242 and OSI-027, Has Cytotoxic Effects In T-Cell Acute Lymphoblastic Leukemia

AMP-Dependent Kinase/mTOR Complex 1 Signaling In T-Cell Acute Lymphoblastic Leukemia: Therapeutical Implications

Temsirolimus, An mTOR Inhibitor, In Combination with Low-Dose Clofarabine in Older Patients with Advanced Acute Myeloid Leukemia: Results of a Phase 2 GIMEMA Study (AML-1107)

Epigenetic Regulation of Lipid Signalling Pathways In Low-Risk MDS Patients During Azacitidine Treatment

Dual Inhibition of Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin with NVP-BEZ235 as a New Therapeutic Option for T-Cell Acute Lymphoblastic Leukemia.

Effect of Erythropoietin Treatment on Lipid Signalling Pathways in Low-Risk MDS Patients.

Erucylphosphohomocholine, the First Intravenously Applicable Alkylphosphocholine, Induces Cell Cycle Arrest, Apoptosis, and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia.

PI-103, a Dual Inhibitor of Class IA Phosphatidylinositol 3-Kinase and Mammalian Target of Rapamycin, Has Cytotoxic Activity in T-Cell Acute Lymphoblastic Leukemia Cells: A New Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia.

Synergistic Proapoptotic Activity of Recombinant TRAIL Plus the Akt Inhibitor Perifosine in Acute Myelogenous Leukemia Cells-a Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

PI-PLCbeta1 Expression in Patients with High-Risk Myelodysplastic Syndromes Is Affected by Azacitidine Treatment.

The AKT Inhibitor, A443654, Induces Cell Cycle Arrest, Apoptosis and Synergizes with Chemotherapeutic Drugs in Multi-Drug Resistant T-Cell Acute Lymphoblastic Leukemia - A Novel Agent for Therapy of Drug Resistant ALL.

The Novel Akt Inhibitor Perifosine Induces Apoptosis, Cell Cycle Arrest and Synergizes with Chemotherapeutic Drugs in Acute Myelogenous Leukemia Cells by a JNK Dependent Mechanism - A Novel Therapeutic Approach for Leukemia Displaying Elevated Akt Signaling.

Roles of Raf/MEK/ERK and PI3K/Akt/mTOR Pathways in Prevention of Apoptosis and Induction of Drug Resistance in Myeloid Hematopoietic Cells.

Dominant Role of Raf/MEK/ERK Signaling in Hematopoietic Cell Cycle Progression, Prevention of Apoptosis and Drug Resistance.

Frequent Elevation of Akt Kinase Phosphorylation in Mononuclear Cells from High-Risk Myelodysplastic Syndrome Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only